Our analysis confirmed that colitis is a dominant digestive irAE, with ipilimumab (anti-CTLA-4) exhibiting significantly stronger signal intensities for colitis compared to anti-PD-1/PD-L1 agents—consistent with previous systematic reviews (Onuki et al., 2018). Here, CTLA4 is linked to colitis.